Repositorio Dspace

The action of 7,8-dihydroxyflavone preserves retinal ganglion cell survival and visual function via the TrkB pathway in NMDA-induced retinal excitotoxicity.

Mostrar el registro sencillo del ítem

dc.contributor.author Gallego-Ortega, Alejandro
dc.contributor.author Galindo-Romero, Caridad
dc.contributor.author Vidal-Villegas, Beatriz
dc.contributor.author Bernal-Garro, José-Manuel
dc.contributor.author de-la-Villa, Pedro
dc.contributor.author Avilés-Trigueros, Marcelino
dc.contributor.author Vidal-Sanz, Manuel
dc.date.accessioned 2026-03-10T11:49:08Z
dc.date.available 2026-03-10T11:49:08Z
dc.date.issued 2025-04
dc.identifier.citation Gallego-Ortega A, Galindo-Romero C, Vidal-Villegas B, Bernal-Garro JM, De La Villa P, Avilés-Trigueros M, et al. The action of 7,8-dihydroxyflavone preserves retinal ganglion cell survival and visual function via the TrkB pathway in NMDA-induced retinal excitotoxicity. Biomedicine & Pharmacotherapy. abril de 2025;185:117944. doi:10.1016/j.biopha.2025.117944
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/25212
dc.description.abstract PURPOSE: To analyze the response of different retinal ganglion cell (RGC) populations to NMDA-induced retinal excitotoxicity and the effect of an intraperitoneal treatment with 7,8-Dihydroxyflavone (DHF), a potent selective TrkB agonist. METHODS: Adult albino rats were treated the day prior to NMDA injection and the three following days with intraperitoneal vehicle (1?%DMSO in 0.09?%NaCl) or DHF (5 mg/kg in vehicle) injections. DHF-afforded protection was studied in the population of Brn3a(+)RGCs, OPN(+)RGCs (?-RGCs), OPN(+) Tbr2(+)RGCs (?ONs-RGCs), OPN(+) Tbr2(-)Brn3a(-)RGCs (?ONt-RGCs) and OPN(+)Brn3a(+)RGCs (?OFF-RGCs) at 3,7,14, or 21 days. The functional response was analyzed longitudinally with full-field electroretinograms. The mechanisms underlying DHF-afforded neuroprotection were assessed by western blot (WB) analysis of the levels of phosphorylated and total TrkB, phosphatidylinositol 3 kinase (PIK3/AKT) and mitogen-activated protein kinase (MAPK). RESULTS: NMDA intravitreal injection resulted in a significant diminution of the mean amplitudes of the pSTR and b-waves, as well as in severe depletion of all RGCs studied except ?ONt-RGCs. DHF treatment resulted in rescued mean amplitudes of the pSTR and b-waves up to 21 days after NMDA. WB analysis revealed an increase in p-TrkB which correlates to the increase of TRKB protein and an increase in normalized pAKT/AKT. pMAPK/MAPK was upregulated earlier and significantly higher in DHF-treated retinas. DHF afforded survival of up to 49?% of the Brn3a(+)RGCs versus 25?% of the vehicle group at 21 days after NMDA, and improved survival of the ?-RGC and ?ONs-RGCs but did not rescue the ?OFF-RGCs. CONCLUSION: Different RGC types exhibit variable susceptibilities to NMDA injury, and DHF-mediated activation of TrkB affords neuroprotection.
dc.language.iso eng
dc.publisher ELSEVIER
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es
dc.subject.mesh Animals
dc.subject.mesh Retinal Ganglion Cells/drug effects/metabolism/pathology
dc.subject.mesh N-Methylaspartate/toxicity
dc.subject.mesh Flavones/pharmacology
dc.subject.mesh Receptor, trkB/metabolism
dc.subject.mesh Cell Survival/drug effects/physiology
dc.subject.mesh Rats
dc.subject.mesh Signal Transduction/drug effects
dc.subject.mesh Male
dc.subject.mesh Neuroprotective Agents/pharmacology
dc.subject.mesh Electroretinography
dc.subject.mesh Vision, Ocular/drug effects
dc.subject.mesh Retina/drug effects
dc.title The action of 7,8-dihydroxyflavone preserves retinal ganglion cell survival and visual function via the TrkB pathway in NMDA-induced retinal excitotoxicity.
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 40056826
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S0753332225001386
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1016/j.biopha.2025.117944
dc.journal.title Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
dc.identifier.essn 1950-6007


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta